Drug intelligence / Profile preview

cisplatin + cyclophosphamide + dexamethasone + etoposide + methotrexate + vincristine

Development stage: Unknown
Lead developer: Michigan State University
Modality: Small Molecules
Administration: Intravenous, Oral, Intrathecal

Overview

This is a combination chemotherapy regimen consisting of six different anticancer drugs. Each component has a distinct mechanism of action: - Cisplatin: A platinum-based alkylating agent that forms DNA crosslinks, preventing DNA replication and transcription - Cyclophosphamide: An alkylating agent that interferes with DNA replication - Dexamethasone: A corticosteroid that reduces inflammation and suppresses immune response - Etoposide: A topoisomerase II inhibitor that prevents DNA unwinding - Methotrexate: An antimetabolite that inhibits dihydrofolate reductase - Vincristine: A vinca alkaloid that binds to tubulin and disrupts microtubule formation This intensive multi-drug regimen is likely used for aggressive or advanced cancers.

Targets

DHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cisplatin + cyclophosphamide + dexamethasone + etoposide + methotrexate + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + cyclophosphamide + dexamethasone + etoposide + methotrexate + vincristine.

Explore the full profile